We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/5/2017 13:59 | Joined your merry band. Looks like a breakout | volsung | |
09/5/2017 13:26 | Yes, glad i added to my holding yesterday. | cfro | |
09/5/2017 12:14 | Cheers, cfro; let's hope DPH does well for us. We seem to be nudging further into breakout territory just now. | saucepan | |
03/5/2017 11:06 | Bought in today. A thankyou goes to Saucepan and woodcutter for bringing the share to my attention. Lovely quite board here which is refreshing to see. So many of the smaller companies boards are often busy with opposing views. I am getting increasingly disorientated and disillusioned with the more smaller, illiquid companies which havent performed well for me this year. My strategy now is one of moving away from these types into the likes of DPH with an emphasis on "quality". | cfro | |
02/5/2017 12:15 | Keep the trolls away! | phillis | |
02/5/2017 12:12 | Price is irrelevant. This is a great GARP share, and they tend to look expensive and have very quiet boards. Back to sleep.... zzzzz | dozey3 | |
02/5/2017 10:42 | Looks to me like a breakout is on the cards here from a lovely consolidation pattern. I am rather surprised this thread is so quiet - but then perhaps not; many private investors would regard a stock priced at £17 as "expensive". | saucepan | |
05/4/2017 17:23 | a little pull back after some profit taking is probably in order. I shall continue to accumulate on any weakness. woody | woodcutter | |
31/3/2017 21:20 | Agreed, Woody, could be a very lucrative deal and one for the long term. | dozey3 | |
31/3/2017 10:24 | and a very interesting one for the future.........if the price falls a little I will add to my 3/5 year portfolio. | anley | |
31/3/2017 06:42 | looks like a further quality deal/acquisition woody | woodcutter | |
30/3/2017 08:05 | added to my holding this morning. chart looks strong woody | woodcutter | |
14/3/2017 10:25 | Getting near your £17 ............ but why not think of £20 when they announce another record year.......but not just yet! | anley | |
02/3/2017 14:16 | £17 ! | phillis | |
27/2/2017 10:25 | Aviva up thier holding before publication of results!! Think about that........ What a good set of results and more to play for by the management. | anley | |
27/2/2017 10:12 | £16 Still with a head of steam! | phillis | |
10/2/2017 13:30 | Whiskers and Fido rule ok. | steeplejack | |
27/1/2017 14:38 | been accumulating a few times since it broke thro' 1400p woody | woodcutter | |
17/1/2017 18:12 | One reason why this company is a success is that the CEO has been able to create a team which is very able in extracting profits from all the acquisitions. When a share goes up on a day like today then there is lot more good news to come over the coming year. Well done the management .......... | anley | |
17/1/2017 07:35 | Trading UpdateThe Board of Dechra issues the following unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31 December 2016.Highlights-- Reported Group revenue for the Period increased by approximately 34% at constant exchange rate (CER) (56% at actual exchange rate (AER)).-- Core Group revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.-- All acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of the Board's expectations.-- Approval by the FDA was achieved for the first major product from the Putney pipeline, a Companion Animal Product (CAP) generic antibiotic, Amoxi-clav.Ian Page, Chief Executive Officer, said:"Our underlying business and acquisitions have performed well, resulting in significant growth in the first half of the 2017 financial year. The Group pipeline has delivered new products and our global presence continues to increase. We remain confident in our strategy, our future prospects and our expectations for full year performance." | steeplejack | |
21/12/2016 17:24 | Bought in to the story today as a one year+ holding............ | anley | |
20/12/2016 08:40 | Been buying quite a few recently woody free stock charts from uk.advfn.com | woodcutter | |
15/12/2016 10:57 | perky today | phillis |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions